Simultaneous determination and pharmacokinetics study of valsartan, sacubitril and its major metabolite in human plasma, urine and peritoneal dialysis fluid in patients with end-stage renal disease by UPLC–MS/MS

Jin, Ying; He, Yi; Di, Xiangjie; Fu, Lisha; Qi, Xiaohui; Liu, Runhan; Li, Zheng; Wang, Yongsheng; Zhong, Hui; Wang, Zhenlei

doi:10.1016/j.jchromb.2022.123402

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, few reports analyzed VAL and SAC with the active metabolite of SAC (LBQ657) using LC-MS/MS 28 and UPLC MS/MS. 29 The current work aims to develop a validated, sensitive, and accurate HPLC coupled with a uorescence detector (FLD) method that can detect, and quantify simultaneously FEX, IBU and LCZ696 analytes (VAL, SAC, and LBQ657) in rat plasma. Furthermore, the presented bioanalytical method proves its applicability to investigate the possible DDIs and PK proles of LCZ696 analytes (VAL, SAC, and LBQ657) in the presence of selected OTC drugs, either FEX or IBU.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bioanalytical HPLC method with fluorescence detector for determination of Entresto™ when co-administered with ibuprofen and fexofenadine: a pharmacokinetic study

Ahmed,

Galal,

Korany

et al. 2024

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Furthermore, few reports analyzed VAL and SAC with the active metabolite of SAC (LBQ657) using LC-MS/MS 28 and UPLC MS/MS. 29…”

Section: Introductionmentioning

confidence: 99%

Bioanalytical HPLC method with fluorescence detector for determination of Entresto™ when co-administered with ibuprofen and fexofenadine: a pharmacokinetic study

Ahmed,

Galal,

Korany

et al. 2024

RSC Adv.

View full text Add to dashboard Cite

show abstract

Simultaneous analysis of sacubitril and valsartan by novel analytical methods with green approach

Tiris,

Ayse Genc,

Erk

2024

Microchemical Journal

View full text Add to dashboard Cite

Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients

Jin

Xue³

et al. 2023

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Background There is little information on the pharmacokinetics and pharmacodynamics of sacubitril/valsartan (SV) in patients with peritoneal dialysis (PD) complicated with hypertension or heart failure (HF). This study was designed to evaluate the pharmacokinetics and pharmacodynamics of SV in PD patients with complications of hypertension or HF. Methods This was an open-label and cross-sectional study investigating PD patients diagnosed with hypertension or New York Heart Association (NYHA) Class II-IV HF. The concentrations of valsartan, sacubitril, and sacubitrilat (LBQ657) were measured by ultra-performance liquid chromatography tandem mass spectrometry in plasma, urine and peritoneal dialysate samples. Pharmacodynamics were evaluated by comparing changes in mean sitting systolic blood pressure (msSBP), mean sitting diastolic blood pressure (msDBP), mean sitting heart rate (msHR), N-terminal-pro B-type natriuretic peptide (NT-proBNP) and left ventricular ejection fraction (LVEF). Results Forty patients with PD were enrolled including 27 (67.5%) patients with hypertension, 4 (10%) patients with HF and 9 (22.5%) patients with both hypertension and HF. This study included three treatment cohorts: 50 mg twice daily (BID), 100 mg once daily (QD) and 100 mg BID. The plasma maximum drug concentrations in the 100 mg BID group were 1995 ± 1499 ng/mL for valsartan, 171 ± 148 ng/mL for sacubitril and 13 686 ± 7418 ng/mL for LBQ657. The 24 h recovery rate of LBQ657 was 3.77% in urine and 2.23% in peritoneal dialysate. After taking SV, msSBP and msDBP decreased by 19.25 ± 10.32 mmHg and 10.10 ± 8.00 mmHg from baseline, respectively. NT-proBNP decreased by 1436.50 (0.00–18198.00) from baseline, while LVEF increased by 5.00 (-0.25–9.25) from baseline after SV treatment. Conclusions PD and residual renal function contributed only to a minor degree to the elimination of LBQ657. Additionally, a dose of 100 mg BID SV is safe and effective in patients with PD with complications of hypertension or HF.

show abstract

Simultaneous determination and pharmacokinetics study of valsartan, sacubitril and its major metabolite in human plasma, urine and peritoneal dialysis fluid in patients with end-stage renal disease by UPLC–MS/MS

Cited by 3 publications

References 28 publications

Bioanalytical HPLC method with fluorescence detector for determination of Entresto™ when co-administered with ibuprofen and fexofenadine: a pharmacokinetic study

Bioanalytical HPLC method with fluorescence detector for determination of Entresto™ when co-administered with ibuprofen and fexofenadine: a pharmacokinetic study

Simultaneous analysis of sacubitril and valsartan by novel analytical methods with green approach

Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients

Contact Info

Product

Resources

About